Is the Cause Finally Clear? A Little-Known Protein May Drive Alzheimer's—and Researchers Have Found a Way to Intervene
Date of publication: August 17, 22:00
A team of scientists has identified an experimental compound, designated 10, that in mouse tests prevented harmful protein clumps from forming in the brain, boosted mitochondrial function, reduced beta-amyloid buildup, and guarded nerve cells against damage. The work was led by Ursula Quitterer, professor of molecular pharmacology at ETH Zurich, and began almost 20 years ago with the examination of brain samples from patients at Ain-Shams Hospital in Cairo. That investigation revealed how an inactive version of the enzyme GRK2 contributes to dementia, causing aggregates to form on mitochondria and increasing the production of beta-amyloid.
In mice, compound 10 blocked GRK2 molecules from aggregating in the brain. The treatment also led to better mitochondrial performance, less beta-amyloid accumulation, and protection against neuronal death. To understand GRK2—an enzyme that enables cells to respond to signals, stress, and strain—the researchers studied tissue samples collected during tumor-removal surgery. GRK2 normally operates in both the heart and the brain, where it helps keep nerve cells functioning properly.
What the Experiments Revealed
The study found unusually high levels of the inactive GRK2 form in brain tissue from people with dementia. In that state, the protein clumps on mitochondria, disrupts their activity, and stimulates beta-amyloid production—creating a self-reinforcing cycle of disease progression. Several chemical compounds were tested in cell cultures and mice. Compound 10 proved particularly promising: it improved heart function and aging-related processes in older mice, and treated animals even developed less grey hair.
A paper describing the work has appeared in the journal Cell Reports Medicine, opening new possibilities for understanding how dementia develops and how it might be treated in the future. With dementia cases continuing to climb worldwide, the search for new therapeutic strategies is especially urgent.
These discoveries could shift the direction of Alzheimer's treatment by highlighting mechanisms that have been largely overlooked. If compound 10 advances to clinical testing, it could offer a fresh weapon against dementia—a critical objective as the number of older adults with the condition grows. The work also reinforces the importance of sustained, long-term research that can ultimately produce practical therapies for complex diseases.
In light of these findings, the discovery of previously unseen mitochondrial plaques in the brains of Alzheimer's patients further emphasizes the complexity of the disease. Understanding these plaques may provide additional insights into the mechanisms of neuronal damage and potential therapeutic avenues that could complement the benefits observed with compound 10.